INTRODUCTION
Lung cancer (LC) is the most common type of tumor, and its incidence ranks first out of the various tumors with a high rate in morbidity and mortality, which is a serious threat to human health worldwide. 1 Early detection of molecular markers is the most effective method of LC prevention; however, the molecular mechanisms underlying LC progression are not well characterized. Therefore, the search for novel therapeutic biomarkers and investigations into the underlying molecular mechanisms may contribute to the development of new treatment and prognostic monitoring strategies for lung carcinoma.
Transcribed ultraconserved regions (T-UCRs) are absolutely conserved among human, chick, dog, mouse, as well as rat genomes. [2] [3] [4] [5] They are a subtype of long non-coding RNAs (LncRNAs) and lack protein-coding capacity; however, T-UCRs take part in human cancer development and progression. Increasing evidence not only suggested that T-UCRs can be used as diagnostic and/or prognostic tumor biomarkers, [6] [7] [8] [9] but they also can act as regulators for protein-coding genes or other non-coding RNAs, and are involved in cancer biology and tumorgenesis. [10] [11] [12] For example, transcribed uc.206 acts as a novel oncogene by targeting the P53 gene and promoting cervical cancer cell growth, which might be beneficial for cervical cancer therapy. 8 Transcribed uc.338 was served as a novel oncogene, which increased expression of matrix metalloproteinase 9 (MMP9) to improve invasion and migration of cancer cells in colorectal carcinoma. 13 Although uc.454 was downregulated in prostate cancer, 6 the clinical significance and biological mechanism of the T-UCR in the development of LC remain largely unknown. In this study, the expression of uc.454 was detected using real-time qPCR in non-small-cell LC (NSCLC) tissues and LC cell lines. In addition, its role was also analyzed in proliferation and apoptosis of LC cells.
RESULTS

Expression of uc.454 in NSCLC Tissues and Cell Lines
uc.454 expression levels were investigated in 100 LC tissues and matched normal lung tissues by real-time qPCR. Expression of uc.454 RNA was significantly lower in the tumor tissues than that of adjacent normal tissues (p < 0.05; Figure 1A ). Next, we measured uc.454 expression in LC cell lines and normal lung 16HBE cells, and found that uc.454 was expressed at a lower level in tumor cell lines (A549, NCI-H2170, NCI-H1299, 95-D, NCI-H2170, and SPC-A-1) than negative control (NC) ( Figure 1B ). Further, we evaluated the correlation between the expression level uc.454 RNA and clinicopathological parameters in LC of patients using a t test. A significant positive correlation was found between a low uc.454 and higher tumor burden and advanced TNM stage (p < 0.05; Figures 1C  and 1D ). These results suggest that a lower uc.454 expression level may be an important factor in lung tumorigenesis and cancer progression.
uc.454 Affected Lung Cancer Cell Proliferation via Regulation of Apoptosis
To investigate the biological role of uc.454 in LC, we established stable uc.454 overexpression and knockdown NCI-H2170 and SPC-A-1 cell lines using transfection. uc.454 expression was confirmed by realtime qPCR (p < 0.05; Figure 2A ). Then, cell proliferation was measured using the Cell Counting Kit-8 (CCK-8) and colony formation assays. The CCK-8 assay showed that uc.454 overexpression led to a significant decrease in the cell proliferation ability in both cell lines. Conversely, the cells of uc.454-siRNA led to a significant increase in tumor cell proliferation compared with that in the control group (p < 0.05; Figure 2B ). Similarly, the colony formation assays revealed that the colony formation ability was significantly decreased after overexpression of uc.454, whereas knockdown of uc.454 expression via small interfering RNA (siRNA) increased the colony formation ability in both the NCI-H2170 (p < 0.05; Figure 2C ) and SPC-A-1 (p < 0.05; Figure 2D ) cell lines. To probe the effects of uc.454 overexpression or knockdown, we performed a flow cytometric analysis on LC cell proliferation. The cell apoptosis ratio of cells overexpressing uc.454 was significantly increased compared with the control. Conversely, knockdown of uc.454 expression reduced cell apoptosis in both the NCI-H2170 (p < 0.05; Figure 2E ) and SPC-A-1 (p < 0.05; Figure 2F ) cell lines. However, the results did not reveal significant changes in cell-cycle progression between the cell lines (data not shown).These findings suggest that uc.454 may be strongly associated with control of the proliferative ability of LC cell lines.
The Impact of uc.454 Overexpression on Tumorigenesis In Vivo
To investigate whether uc.454 affected tumorigenesis in vivo, we inoculated into nude mice NCI-H2170 cells transfected with MSCV-uc.454 or control. All of the mice developed xenograft tumors at the injection site. As shown in Figure 3A , tumor growth was significantly slower in the uc.454 group than in the NC up to 4 weeks post-injection. The average tumor volume in the uc.454 group was obviously lower than the averages in the control group (p < 0.05; Figure 3B ). The overall survival (OS) time showed that the mice transfected with uc.454 had a better survival rate (p < 0.05; Figure 3C ). We also found that the tumors developed from the uc.454 cells displayed weaker HSPA12B staining than the tumors formed by the control group cells in the immunohistochemistry (IHC) analysis ( Figure 3D ). T-UCRs, a subtype of Lnc-RNAs, can regulate their neighboring protein-coding genes. [14] [15] [16] Recently, studies found that high uc.454 expression was lower in prostatic cancer patients than that of NC. 17 The HSPA12B gene (chr20: 0 UTR of HSPA12B. To verify further that HSPA12B is downregulated directly by uc.454, we performed an RNA immunoprecipitation (RIP) assay with an antibody against HSPA12B using cell extracts from NCI-H2170 and SPC-A-1 via transfection of uc.454. The results showed that the HSPA12B protein specifically interacted with uc.454 RNA. uc.454 was enriched in the anti-HSPA12B RIP fraction relative to the input compared with the IgG fraction in both the NCI-H2170 and SPC-A-1 cell lines ( Figure 5D ). These findings suggest that HSPA12B is a direct target of uc.454, and overexpression of uc.454 may accelerate to inhabit expression of HSPA12B.
uc.454 Affecting Cell Growth and Apoptosis Regulated HSPA12B Expression
To test this hypothesis, we performed real-time qPCR and western blotting to evaluate the transcription and protein expression level of HSPA12B after transfection of uc.454 or uc.454-siRNA. Our data showed the HSPA12B in mRNA and protein levels is increased compared with control groups after transfection of uc.454-siRNA (p < 0.05; Figure 5A ), whereas the HSPA12B expression level was significantly decreased upon overexpression of uc.454 ( Figure 5B ). These results suggest that HSPA12B is downregulated by uc.454 at the transcription and translational level. Immunofluorescence (IF) showed that overexpression of uc.454 reduced the HSPA12B protein expression level ( Figure 5C ).
Knockdown of HSPA12B Induced Apoptosis by Regulating Bcl-2 Protein Family Expression
To investigate the biological function of HSPA12B in lung carcinoma, we used two siRNAs to knock down HSPA12B expression. The HSPA12B expression level was confirmed by real-time qPCR and western blotting with siRNA or NC for 48 hr. The HSPA12B mRNA and protein expression levels were substantially downregulated with siRNA compared with the NC group (p < 0.05; Figures  6A and 6E ). The CCK-8 assay showed that HSPA12B-siRNA led to a significant decrease in tumor cell proliferation (p < 0.05; Figure 6B ). The colony formation assay showed that HSPA12B-siRNA decreased the colony formation ability (p < 0.05; Figure 6C ). Next, we investigated the effects of HSPA12B on cell apoptosis by flow cytometer. The apoptotic cell proportions were significantly increased in the HSPA12B-siRNA group compared with the NC group (p < 0.05; Figure 6D) . To elucidate the downstream pathway of HSPA12B, we analyzed the expression of the apoptosis-related Bcl-2 protein family members (Bax and Bcl-2) and Caspase-3 activation after transfection with siRNA in both the NCI-H2170 cells ( Figure 6E ). Knockdown of HSPA12B led to an increased level of the pro-apoptotic protein (Bax) and a decreased level of the anti-apoptotic protein (Bcl-2), suggesting that downregulation of HSPA12B would have the same biological effect. Hence, we concluded that HSPA12B expression induced Caspase-3-dependent apoptosis in LC cells, and thus exerted a critical effect on LC cell apoptosis.
uc.454 Exerts Its Effect on the Inhibition of Apoptosis through HSPA12B
We conducted rescue assays to determine whether HSPA12B mediated the uc.454-induced decrease in LC cell proliferation. After transfection with uc.454-MSCV, the NCI-H2170 and SPC-A-1 cells were cotransfected again with plasmid complementary DNA (pcDNA)-HSPA12B. The CCK-8 assay showed that HSPA12B overexpression rescued the uc.454-induced increase in LC cell proliferation (p < 0.05; Figure 7A ).The colony formation assay showed that HSPA12B overexpression increased clonogenic survival (p < 0.05; Figures 7B and 7C) . Consistently, the flow cytometry results also showed that HSPA12B overexpression compromised the effects of uc.454 overexpression on LC apoptosis (p < 0.05; Figures  7D and 7E ). Western blotting analysis to measure activated Caspase3 and Bcl-2 family protein (Bax and Bcl-2) expression after pcDNA-HSPA12B co-transfection indicated that HSPA12B overexpression led to an increased level of the anti-apoptotic protein (Bcl-2) and decreased level of the pro-apoptotic protein (Bax) (Figure 7F) . These findings suggest that overexpression of the uc.454 in LC may reduce the HSPA12B protein level by accelerating HSPA12B protein turnover, and that the low HSPA12B abundance can decrease Bcl2 expression and increase Bax expression, thereby inducing LC cell apoptosis.
DISCUSSION
T-UCRs are a subtype of Lnc-RNAs, lack protein-coding capacity, and are absolutely conserved among human, chick, dog, and mouse, as well as rat genomes. 2-5 T-UCRs have been confirmed to play crucial bio-functions in human diseases, including cancer. Increasing evidence suggests that Lnc-RNAs may function as oncogenes or tumor suppressors. [18] [19] [20] Recent studies indicated uc.73 influenced apoptosis in colon cancer cells and that uc.338 inhibited the growth of hepatocellular carcinoma cells. 19, 21, 22 The expression type and amount of T-UCRs have been confirmed to be closely related to the survival rates of cancer patients. 7, 20, 23 In this study, expression of uc.454 was significantly lower in NSCLC tissues than that in adjacent normal lung tissues. It was also less expressed in LC cell lines than in normal lung cells. These results suggested that uc.454 was a novel tumor suppressor LC. Moreover, comparisons of uc.454 expression in clinical tumor specimens showed that uc.454 was low expressed in bigger tumors and tumors with more advanced stages, which indicated that uc.454 might suppress LC development. However, we lack sufficient clinical prognostic data. In vitro experiments showed that when uc.454 was upregulated, cell proliferation was inhibited and cell apoptosis was induced. Meanwhile, when uc.454 was downregulated, the results were just the opposite. Because uc.454 may play a suppressive role in LC, overexpressed uc.454 of LC cell lines were used for in vivo experiments, and these results supported that upregulating uc.454 inhibit tumor formation, [24] [25] [26] [27] In LC, HSPA12B could downregulate AKAP12, which in turn increased expression of VEGF, thereby activating expression of Cox-2 and stimulating lung tumor growth. 28 In this study, we found that HSPA12B was negatively regulated by uc.454 at the posttranscriptional level, via a specific target site within the 3 0 UTR. RIP experiments proved further that uc.454 is interacted directly with the HSPA12B protein. In vitro results showed that upregulating or downregulating uc.454 could change mRNA expression of HSPA12B. These data showed that HSPA12B is a direct target of uc.454. Additionally, IF assays showed uc.454 and HSPA12B were locating in nucleus of LC cells, and upregulating uc.454 resulted in down-expression of HSPA12B.
In order to explore the role of HSPA12B in LC, we used siRNA to downregulate HSPA12B expression. In vitro results showed that as HSPA12B reduced, proliferations of LC cell lines were inhibited, and apoptosis was induced. Apoptosis is associated with pro-(Bax and Bid) and anti-apoptotic (Bcl-2 and Bcl-xL) genes. [29] [30] [31] Besides, the Bcl-2 protein family is the upstream pathway, which affects caspase-3 activation. 29, [32] [33] [34] In this study, western blotting displayed that antiapoptotic protein Bcl-2 was decreased, whereas pro-apoptotic protein Bax and cleaved-Caspase-3 were increased after overexpression of uc.454. Moreover, rescue experiments showed that cell proliferations, which were inhibited by overexpression of uc.454, were rescued when HSPA12B was upregulated. On the other hand, cell apoptosis, which was induced by uc.454 overexpression, could be abrogated by upregulating HSPA12B. Western blotting demonstrated that uc.454-induced Bcl-2 expression was partially abrogated by HSPA12B upregulation. Besides, overexpression of Bax and cleaved-Caspase-3 caused by uc.454 upregulation were also partially abrogated by HSPA12B overexpression. Evidence above indicated that uc.454 could regulate the expression of HSPA12B and then affect the ratio of Bcl-2/Bax, which finally induced LC cells apoptosis.
In summary, our results suggested that uc.454 played a suppressive role in LC cell growth. It can induce LC apoptosis by negatively modulating HSPA12B expression. The uc.454/HSPA12B axis furthered our understanding of the molecular mechanisms involved in LC apoptosis, which may potentially serve as a therapeutic target for LC.
MATERIALS AND METHODS
Tumor Specimens and Cell Lines
98 NSCLC specimens were obtained from the Department of Thoracic Surgery, The Affiliated Hospital of Yangzhou University (YZU; Yangzhou, China). The study was approved by the Research Ethics Committee with YZU, and written informed consent was obtained from all patients. The samples were frozen in liquid nitrogen immediately after surgical removal. LC cell lines (NCI-H2170 and SPC-A-1) and normal lung cell line (16HBE) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The 293T cell line was purchased from the Chinese Peking Union Medical College Cell Bank (Beijing, China). All cell lines were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) (HyClone, VIC, Australia) and antibiotics (1% penicillin/streptomycin; GIBCO) at 37 C in a humidified atmosphere containing 5% CO 2 .
RNA Extraction and Real-Time qPCR Analysis
Total RNA was extracted from the NSCLC specimens or cells using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. The concentrations were quantified using the NanoDrop 2000 (NanoDrop, Wilmington, DE, USA). For the real-time qPCR, RNA was reverse transcribed to cDNA www.moleculartherapy.org using a PrimeScript First Strand cDNA synthesis kit (Takara Bio, Dalian, China). The real-time qPCR was performed using the 7500 Real-Time PCR System (Applied Biosystems, USA) with the Fast Start Universal SYBR Green Master (Roche, USA). The results were normalized to U6 small RNA expression. The specific primers are listed in Table S1 . All procedures were performed in triplicate.
Transient Transfection and Infection
SPC-A-1 and NCI-H2170 cells were transfected with uc.454-murine stem cell virus (MSCV) plasmid, siRNA plasmid, and control for 48 hr before further experiments. The transfected cells were incubated at 37 C with 5% CO 2 . The uc.454 and HSPA12B RNA level in the transfected LC cells were identified by real-time qPCR.
Full-length uc.454-shRNA or uc.454 was cloned into retroviral vector MSCV plasmid at the Noncoding RNA Center, YZU (Yangzhou, China) and sequence-confirmed by Sangon Biotech (Shanghai, China). 293T cells were seeded in 100-mm dishes 1 day prior to transfection with 10 mg of uc.454-shRNA or uc.454 vectors and 3 mg of GagPol and 3 mg of pHIT123 plasmids using Lipofectamine 2000 (Invitrogen Life Technologies). The retroviral supernatants were collected 48 hr after transfection and stored at 80 C in freezer. 5-8 mL of supernatants containing the uc.454-shRNA or uc.454 virus together with 8 mg/mL polybrene (SigmaAldrich) was used to infect LC cell lines. Empty vectors or vectors with scramble sequences were used as NCs. The RNA levels of uc.454 in LC cells were measured by real-time qPCR.
Dual-Luciferase Reporter Assay
The full-length 3 0 UTR of HSPA12B was amplified by PCR from genomic DNA and cloned into the EcoRI and XhaI sites of pGL3-BS vector (Promega, WI, USA). The primers for HSPA12B 3 0 UTR were as follows: 5 0 -aacgatagttctgcagtctg-3 0 and 5 0 -ctgttgcaagccagttagag-3 0 . The mutant construct of HSPA12B 3 0 UTR was generated using a QuikChange mutagenesis kit (Stratagene, Heidelberg, Germany). Co-transfection of reporter vectors and uc.454 mimics or NC was performed using Lipofectamine 2000 (Invitrogen, San Diego, CA, USA). After 48 hr, dual-luciferase activity was measured using a dual-luciferase reporter assay system according to the instructions (Promega, WI, USA).
Cell Proliferation Assay
Cell proliferation was assayed using the CCK8 assay according to the instructions. For the cell proliferation assay, transiently transfected cells were seeded into 96-well plates at a density of approximately 2,000 cells per well, and cell proliferation was tested approximately every 24 hr. After incubation with 10 mL of the CCK-8 reagent (Beyotime Institute of Biotechnology, Shanghai, China) for 2 or 4 hr, the absorbance at 450 nm was measured for each well. The assay was performed in five replicate wells, and three parallel experiments were conducted for each sample.
Colony Formation Assay
For the colony formation assay, transfected cells (1,000 cells/well) were seeded into each well of a six-well plate and maintained in medium containing 10% FBS in an incubator with 5% CO 2 at 37 C. After 2 weeks, the colonies were fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich, St. Louis, MO, USA) for 20 min. Colony formation was determined by counting the number of stained colonies. Triplicate wells were measured in each treatment group.
Cell Apoptosis Assay
LC cells were seeded in six-well plates and transiently transfected with uc.454 and the control vector. After 2 days, the cells were washed with cold PBS twice and subsequently treated with 5 mL of Annexin V and 10 mL of propidium iodide (PI) using Alexa Fluor 488 Annexin V/ Dead Cell Apoptosis Kit (Invitrogen) to determine the cell apoptosis according to the protocol and then analyzed by a flow cytometer (BD Biosciences, CA, USA).
Western Blotting Assay
A total protein extraction kit (KeyGen Biotech, Nanjing, China) was used to extract total proteins. The procedures were followed according to the kit manual. Cell protein lysates were separated by 10% SDS-PAGE (Bio-Rad, Hercules, CA, USA) and transferred to a polyvinylidene fluoride (PVDF) membrane (Merck Millipore, Darmstadt, Germany) using a standard wet transfer apparatus. Then, the membranes were blocked in 5% non-fat milk in Tris-buffered saline with 0.05% Tween 20 (TBST) at room temperature for 2 hr, incubated overnight with the primary anti-HSPA12B (1:1,000 dilution, ab116082; Abcam), anti-Bcl2 (1:1,000, ab32124; Abcam), antiBax (1:1,000, ab77566; Abcam), anti-cleaved Caspase-3 (1:1,000, ab2302; Abcam), or anti-GAPDH antibody (1:1,000 dilution, AF0006; Beyotime); anti-GAPDH was used as an internal control. The membrane was washed with TBST three times for 5 min per wash. Then, the PVDF membrane was incubated in blocking buffer containing the diluted secondary antibody at room temperature for 2 hr. Finally, protein bands were detected on FluorChem FC2 Imaging System (Alpha Innotech, San Leandro, CA, USA).
IHC
For the IHC analysis, fresh specimens were cryopreserved and routinely processed into frozen sections. Then, 4-mm-thick sections were prepared, and immunohistochemical staining with a streptavidin-biotin immunoperoxidase assay was performed using rabbit antibodies against HSPA12B (1:400 dilution, ab116082; Abcam). The slides were imaged under a light microscope (Leica, Germany) at 100Â magnification. Brown staining in the cells was considered a positive signal. 
IF
When the coverage of cells on the coverslips reached approximately 90%, the cells were fixed for 15 min at room temperature in 4% paraformaldehyde. After aspiration of the fixative, the samples were rinsed three times in 1Â PBS for 5 min per wash and blocked in Blocking Buffer (1Â PBS supplemented with 0.3% Triton X-100 [Sangon Biotech] and 5% normal goat serum [Life Technologies]) for 60 min. After incubation with the primary antibody overnight at 4 C, the samples were rinsed three times in 1Â PBS for 5 min per wash and then incubated with the anti-rabbit IgG secondary antibody (1:200) for 60 min at room temperature in the dark. Normal rabbit IgG (Life Technologies) was used as the NC. The antibodies used for the IF assay were as follows: rabbit anti-HSPA12B (Abcam), rabbit anti-IgG (Merck Millipore), and anti-rabbit IgG (Alexa Fluor 488 Conjugate) (Life Technologies). The nuclei were labeled using DAPI (Sangon Biotech), and the cells were visualized using a Ti-S fluorescence microscope (Leica DM 5000B; Leica, Wechsler, Germany).
Xenograft Study
All animal experiments were conducted according to the guidelines of the YZU Institutional Animal Care and Use Committee. Healthy, 5-week-old athymic BALB/c mice were maintained under specific pathogen-free conditions. The 40 mice were randomly divided into two groups (NC and uc.454). A total of 2 Â 10 6 NCI-H2170 cells were transfected with each retrovirus in 0.2 mL of PBS and injected into the back of nude mice. The tumor volumes were examined every 4 days after the tumors started to grow. Four weeks after injection, the mice were sacrificed, and the tumor was measured in volumes and weights. The primary tumors were excised, collected, and prepared for IHC staining. The other 20 mice injected with different NCI-H2170 cells were randomly divided into two groups for OS time research.
RNA Immunoprecipitation
The RIP experiments were performed using a Magna RIP RNABinding Protein Immunoprecipitation Kit (Millipore) according to the manufacturer's instructions. Antibodies against HSPA12B used for the RIP assays were purchased from Abcam. The results were confirmed by real-time qPCR and electrophoresis on a 1% agarose gel.
Statistical Analysis
All statistical analyses were performed using 16.0 software package (SPSS, Chicago, IL, USA). All graphs were created using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). The clinicopathological findings were compared using an unpaired t test or Pearson x2 test. One-way ANOVA based on the normal distribution and equal variance assumption test were adopted for the statistical comparisons. The OS rates were calculated by the Kaplan-Meier method with the log-rank test applied for comparison. The results are expressed as the mean ± SD, and p < 0.05 is considered significant.
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